These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 16454732)

  • 1. Mechanisms of CTLA-4-Ig in tolerance induction.
    Alegre ML; Fallarino F
    Curr Pharm Des; 2006; 12(2):149-60. PubMed ID: 16454732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4: From mechanism to autoimmune therapy.
    Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
    Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA4-Ig: a novel immunosuppressive agent.
    Najafian N; Sayegh MH
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
    Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
    J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
    Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
    J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
    Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
    Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
    Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
    Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
    Zhou T; Weaver C; Linsley PS; Mountz JD
    Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD28-B7 costimulatory pathway and its role in autoimmune disease.
    Daikh D; Wofsy D; Imboden JB
    J Leukoc Biol; 1997 Aug; 62(2):156-62. PubMed ID: 9261329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance.
    Romo-Tena J; Gómez-Martín D; Alcocer-Varela J
    Autoimmun Rev; 2013 Oct; 12(12):1171-6. PubMed ID: 23851140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation.
    Dengler TJ; Szabo G; Sido B; Nottmeyer W; Zimmerman R; Vahl CF; Hünig T; Meuer SC
    Transplantation; 1999 Feb; 67(3):392-8. PubMed ID: 10030284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
    Kosmaczewska A; Ciszak L; Boćko D; Frydecka I
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):39-46. PubMed ID: 11266089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4Ig: uses and future directions.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):132-42. PubMed ID: 19519590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
    Rennert P; Furlong K; Jellis C; Greenfield E; Freeman GJ; Ueda Y; Levine B; June CH; Gray GS
    Int Immunol; 1997 Jun; 9(6):805-13. PubMed ID: 9199963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of co-stimulation in airway inflammation.
    Djukanovic R
    Clin Exp Allergy; 2000 Jun; 30 Suppl 1():46-50. PubMed ID: 10849475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.